IDEXX Laboratories (IDXX) Stock Price, News & Analysis

Company Overview

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions. The company also operates commercial reference laboratories that provide routine and specialty testing, and offers software and connectivity platforms that deliver laboratory results, imaging and practice-management functionality to veterinary practices. In addition to companion animal diagnostics, IDEXX provides testing and monitoring solutions for dairy herd management, livestock health and water quality.

Founded in the early 1980s and based in Maine, IDEXX has grown into a multinational business with operations and customers across North America, Europe, the Asia-Pacific region and Latin America. Its customer base spans independent and corporate veterinary practices, academic and research institutions, municipal and industrial water utilities, and participants in the food supply chain. The company emphasizes recurring revenue streams from consumables and laboratory services alongside instrument sales, supported by ongoing research and development efforts to expand diagnostic capabilities and digital offerings.

IDEXX positions itself as a technology-driven diagnostics company focused on improving decision-making for animal and public health. Its strategy centers on broadening its diagnostic menu, strengthening laboratory and digital service offerings, and supporting veterinary and public health customers with integrated solutions that aim to improve clinical outcomes and operational efficiency.

Key Stats

• Today's Range: $550.45 to $578.42
• 50-Day Range: $553.66 to $660.71
• 52-Week Range: $471.74 to $769.98
• Volume: 303,553 shs
• Average Volume: 524,609 shs
• Market Capitalization: $45.83 billion
• P/E Ratio: 44.14
• Dividend Yield: N/A
• Price Target: $751.00
• Consensus Rating: Moderate Buy

IDEXX Laboratories Stock Analysis - MarketRank™

IDEXX Laboratories scored higher than 80% of companies evaluated by MarketBeat, and ranked 114th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 7 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

IDEXX Laboratories has a consensus price target of $751.00, representing about 30.2% upside from its current price of $576.75.

Amount of Analyst Coverage

IDEXX Laboratories has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.45%

Earnings Growth

Earnings for IDEXX Laboratories are expected to grow by 12.45% in the coming year, from $14.54 to $16.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEXX Laboratories is 44.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.36.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEXX Laboratories is 44.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.35.

Price to Earnings Growth Ratio

IDEXX Laboratories has a PEG Ratio of 3.42. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IDEXX Laboratories has a P/B Ratio of 28.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.62% of the float of IDEXX Laboratories has been sold short.

Short Interest Ratio / Days to Cover

IDEXX Laboratories has a short interest ratio ("days to cover") of 4.09.

Change versus previous month

Short interest in IDEXX Laboratories has recently increased by 8.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEXX Laboratories does not currently pay a dividend.

Dividend Growth

IDEXX Laboratories does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.92

News Sentiment

IDEXX Laboratories has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for IDEXX Laboratories this week, compared to 6 articles on an average week.

Search Interest

6 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

1 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,862,109.00 in company stock.

Percentage Held by Insiders

0.79% of the stock of IDEXX Laboratories is held by insiders.

Percentage Held by Institutions

87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IDXX Stock Analysis - Frequently Asked Questions

How have IDXX shares performed this year?

IDEXX Laboratories' stock was trading at $676.53 on January 1st, 2026. Since then, IDXX stock has decreased by 14.7% and is now trading at $576.7490.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings data on Tuesday, May, 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories's revenue was up 14.3% on a year-over-year basis.
Read the conference call transcript.

Who are IDEXX Laboratories' major shareholders?

Top institutional investors of IDEXX Laboratories include Bank of New York Mellon Corp (1.89%), Principal Financial Group Inc. (1.11%), Montrusco Bolton Investments Inc. (0.43%) and Bessemer Group Inc. (0.40%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, Nimrata Hunt, Michael G Erickson, James F Polewaczyk, George Fennell, Michael Lane, Sharon E Underberg, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:IDXX
• CIK: 874716
• Web: www.idexx.com
• Phone: (207) 556-0300
• Fax: 207-556-4346
• Employees: 11,000
• Year Founded: 1983

Price Target and Rating

• Average Price Target for IDEXX Laboratories: $751.00
• High Price Target: $830.00
• Low Price Target: $640.00
• Potential Upside/Downside: +30.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $13.07
• Trailing P/E Ratio: 44.23
• Forward P/E Ratio: 39.69
• P/E Growth: 3.42
• Net Income: $1.06 billion
• Net Margins: 24.62%
• Pretax Margin: 30.77%
• Return on Equity: 69.78%
• Return on Assets: 31.91%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 1.23
• Quick Ratio: 0.90

Sales & Book Value

• Annual Sales: $4.30 billion
• Price / Sales: 10.65
• Cash Flow: $15.46 per share
• Price / Cash Flow: 37.33
• Book Value: $20.10 per share
• Price / Book: 28.71

Miscellaneous

• Outstanding Shares: 79,430,000
• Free Float: 78,798,000
• Market Cap: $45.84 billion
• Optionable: Optionable
• Beta: 1.58